Trametinib: Phase I/II data

Data from 77 evaluable metastatic melanoma patients with V600 BRAF mutations in the dose-escalation portion of a 3-part Phase I/II trial showed that twice-daily oral dabrafenib plus once-daily oral trametinib produced an ORR of 56%, including 4 complete responses and 39 partial

Read the full 423 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE